Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects With Mild-to-Moderate Psoriasis Vulgaris

Trial Profile

A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects With Mild-to-Moderate Psoriasis Vulgaris

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2018

At a glance

  • Drugs Betamethasone-dipropionate/calcipotriol (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors MC2 Therapeutics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 21 Aug 2018 According to a MC2 Therapeutics Media Release, full data from the trial will be presented at upcoming medical conferences, and plans to submit a New Drug Application (NDA) to FDA in the first half of 2019.
    • 21 Aug 2018 According to a MC2 Therapeutics Media Release, primary endpoint (PGA) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top